At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Market Closed 09-04 16:00:00 EDT
25.05
+0.81
+3.34%
盘后24.95
-0.10-0.40%
19:30 EDT
High25.17Low24.00Vol421.76K
Open24.17D1 Closing24.24Amplitude4.83%
Mkt Cap1.48BTradable Cap932.70MTotal Shares59.16M
T/O10.46MT/O Rate1.13%Tradable Shares37.23M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vor Bio files automatic mixed securities shelf
TIPRANKS  ·  09-05 04:40
Vor Bio files automatic mixed securities shelf
Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing
THOMSON REUTERS  ·  09-05 04:31
Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing
Vor Bio Grants 83,600 Stock Options, 17,900 RSUs to New Hires Under Inducement Plan
Reuters  ·  09-05 04:05
Vor Bio Grants 83,600 Stock Options, 17,900 RSUs to New Hires Under Inducement Plan
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)
TIPRANKS  ·  08-31
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)
Citi Remains a Buy on Vor Biopharma (VOR)
TIPRANKS  ·  08-13
Citi Remains a Buy on Vor Biopharma (VOR)
Vor Biopharma is Maintained at Neutral by Wedbush
Dow Jones  ·  08-13
Vor Biopharma is Maintained at Neutral by Wedbush
Vor Biopharma (VOR) Receives a Hold from Wedbush
TIPRANKS  ·  08-12
Vor Biopharma (VOR) Receives a Hold from Wedbush
Wedbush Adjusts Price Target on Vor Biopharma to $27 From $18, Keeps Neutral Rating
MT Newswires Live  ·  08-11
Wedbush Adjusts Price Target on Vor Biopharma to $27 From $18, Keeps Neutral Rating
Vor Biopharma Shares Drop After Q2 Results
MT Newswires Live  ·  08-11
Vor Biopharma Shares Drop After Q2 Results
Vor Biopharma Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-11
Vor Biopharma Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs
Reuters  ·  08-11
Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs
Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate
Benzinga Earnings  ·  08-11
Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate
Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss
MT Newswires Live  ·  08-11
Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss
Vor Biopharma Q2 Net Income USD -62.8 Million VS. Ibes Estimate USD -35.7 Million
THOMSON REUTERS  ·  08-11
Vor Biopharma Q2 Net Income USD -62.8 Million VS. Ibes Estimate USD -35.7 Million
Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones  ·  08-11
Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio Grants Stock Options for 32,550 Shares, RSUs for 6,900 Shares to New Hires Under Inducement Plan
Reuters  ·  08-04
Vor Bio Grants Stock Options for 32,550 Shares, RSUs for 6,900 Shares to New Hires Under Inducement Plan
RA Capital Healthcare Fund Disposes of 213 Vor Biopharma Shares Worth $4,206.75
Reuters  ·  07-22
RA Capital Healthcare Fund Disposes of 213 Vor Biopharma Shares Worth $4,206.75
Vor Biopharma Director David Zaccardelli Files Initial Beneficial Ownership Statement
Reuters  ·  07-10
Vor Biopharma Director David Zaccardelli Files Initial Beneficial Ownership Statement
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
TIPRANKS  ·  07-08
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors
Dow Jones  ·  07-08
Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--